0R0T.L - Amgen Inc.
| Previous close | 247.13 |
| Open | 245.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 245.74 - 246.69 |
| 52-week range | 245.74 - 246.69 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 0.24 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.
- Yahoo Finance Video
Home Depot, FTC blocks Amgen deal, Comcast's Hulu stake: Tuesday's top headlines
The Yahoo Finance Live team breaks down Tuesday's biggest stories, including Home Depot earnings report, the FTC suing to block Amgen's deal to buy Horizon Therapeutics, and Comcast's talks to sell its Hulu stake to Disney.
- Yahoo Finance Video
Lowe's, Horizon Therapeutics, AMD: Stocks moving ahead of the close
The Yahoo Finance Live team discusses stocks to watch at the closing bell, including Lowe's, Horizon Therapeutics, AMD, and Nvidia.
- Yahoo Finance Video
FTC sues to block Amgen's $27.8 billion deal to acquire Horizon Therapeutics
Yahoo Finance healthcare reporter Anjalee Khemlani joins the Live Show to discuss details surrounding the FTC suing biopharmaceutical giant Amgen Inc and its plan to block Amgen's $27.8 billion deal to acquire Horizon Therapeutics.
- Yahoo Finance
FTC sues to block Amgen's $28B acquisition of Horizon Therapeutics
The regulator said its decision "sends a clear signal to the market" about consolidation in the pharmaceutical market, though analysts expect the deal will still go through despite delays.
- Yahoo Finance Video
FTC to challenge Amgen's $28 billion deal with Horizon Therapeutics: Report
Yahoo Finance Live discusses the sharp decline of Horizon Therapeutics shares after a report surfaced that the FTC is planning to sue to block Amgen's $28 billion purchase of the drugmaker.
- Yahoo Finance
Novartis CEO criticizes US, EU efforts to curb drug company power
Novartis CEO pushes back against government attempts to direct pharma R&D
- Yahoo Finance
Medical research has driven 'the last 200 years of economic expansion': Michael Milken
Health investment and innovation has been on a roller coaster as a result of the pandemic. But the momentum needs to continue, according to Michael Milken.
- Yahoo Finance Video
Stocks moving in after hours: AMD, Snap, Match Group, Electronic Arts, Amgen
Yahoo Finance Live co-host Seana Smith discusses stocks moving in after-hours trading.
- Yahoo Finance Video
Amgen set to acquire Horizon Therapeutics in $26.4 billion deal
Amgen will acquire Horizon Therapeutics for more than $26 billion as the company dives deeper into rare disease treatment.
- Yahoo Finance Video
Amgen to acquire Horizon Therapeutics for $27.8 billion
Yahoo Finance's Anjalee Khemlani explains news of a major biotech merger as Amgen is set to acquire Horizon Therapeutics.
Yahoo Finance VideoAmgen to buy Horizon Therapeutics, Shein mulls becoming a marketplace, U.S. to announce nuclear breakthrough
Notable business headlines include Amgen’s $26.4 billion acquisition of Horizon Therapeutics, Shein considering becoming an online marketplace, and expectations that the U.S. Department of Energy will announce a nuclear fusion breakthrough.
- Simply Wall St.
Only Three Days Left To Cash In On Amgen's (NASDAQ:AMGN) Dividend
Amgen Inc. ( NASDAQ:AMGN ) is about to trade ex-dividend in the next 3 days. Typically, the ex-dividend date is one...
- Zacks
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
- Zacks
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Amgen (AMGN) closed at $249.75, marking a -0.78% move from the previous day.
- Zacks
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Yahoo Finance Video
Stocks: Tech leads gains, home builders fall, Sherwin-Williams sinks
Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.
- Zacks
Amgen (AMGN) Gains As Market Dips: What You Should Know
Amgen (AMGN) closed at $245.95 in the latest trading session, marking a +0.07% move from the prior day.
- Zacks
Healthcare ETFs in Focus Ahead of Q2 Earnings
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
- Motley Fool
2 Rock-Solid Dividend Stocks to Buy Right Now
These two dividend-paying pharmaceutical titans ought to keep crushing the broader markets for the foreseeable future.
- Motley Fool
2 Dividend Growth Stocks to Buy and Hold for Decades
Two excellent examples right now are Amgen (NASDAQ: AMGN) and Apple (NASDAQ: AAPL). Both businesses generate plenty of cash flow, have been raising their dividend payments in recent years, and investors shouldn't expect those trends to end anytime soon. Drugmaker Amgen currently pays a dividend yield of 3.1%, which is easily more than the S&P 500 average of 1.7%.
- Zacks
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Simply Wall St.
What You Need To Know About Amgen Inc.'s (NASDAQ:AMGN) Investor Composition
The big shareholder groups in Amgen Inc. ( NASDAQ:AMGN ) have power over the company. Institutions often own shares in...
